CRF receptor antagonists and methods relating thereto

US7652035B2 · kind B2 · utility

Assignees

• Neurocrine Biosciences, Inc. · US
• SB Cork · IE

Inventors

• Marion Lanier · San Diego, US
• Manisha Moorjani · San Diego, US
• John Tellew · Village of La Jolla, US
• John Williams · San Diego, US

Key dates

• Filing date: Oct 17, 2005
• Grant date: Jan 26, 2010
• Expiry date: Jun 17, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure:and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2, n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonists in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.